London (ots/PRNewswire) - - First EMEA Licensed Treatment Specifically for LGS Offers New Hope for Patients With Epilepsy Eisai Europe Limited, (Headquarters: London, Chairman and CEO Yutaka Tsuchiya) today announced publication of the results of a major study of its new anti-epileptic agent Inovelon (rufinamide) indicated for adjunctive therapy in ...
London (ots/PRNewswire) - Eisai Europe Ltd announced today that results from 9 clinical data abstracts about compounds in the company's oncology pipeline, product portfolio and preclinical oncology research have been accepted for presentation at the 44th Annual Meeting of the American Society of Clinical Oncology ...
London (ots/PRNewswire) - - Phase II Data Presented at ASCO Showed Acceptable Tolerability Profile, with Low Incidence of Grade 3 and 4 Neuropathy Eisai Europe Ltd. The investigational chemotherapeutic agent eribulin mesylate (E7389) demonstrated activity in a heavily pretreated population of women with ...
London (ots/PRNewswire) - Eisai Limited, the licence holder of Aricept(R) (donepezil hydrochloride) and Pfizer Limited, its co-promotion partner, announced today that Eisai has applied to the Court of Appeal for permission to appeal the recent High Court ruling on the process by which the National Institute for Health and Clinical Excellence (NICE) reached its ...
London (ots/PRNewswire) - - First Treatment Licensed Specifically for LGS Offers New Hope for Patients With Epilepsy Eisai Europe Limited, (Headquarters: London, President Yutaka Tsuchiya) today announced the launch in Germany and Scandinavia of its new anti-epileptic agent Inovelon (rufinamide) indicated for adjunctive therapy in Lennox-Gastaut Syndrome ...